|
|
Article: Actonel(R) Provides Low Incidence of Vertebral Fracture in Osteoporosis Patients Through 7 Years.
- Article from:
- PR Newswire
- Article date:
- June 19, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
In a long-term clinical trial of Actonel(R) (risedronate sodium tablets), a low incidence of new vertebral fractures was maintained over 7 years of treatment. The new study, presented today at ENDO 2003, the 85th annual meeting of The Endocrine Society (ENDO), examined the long-term safety profile and sustained efficacy of Actonel in the treatment of postmenopausal osteoporosis.
"Osteoporosis is treated over a number of years, so long-term protection against fractures is critical," said Jean-Marc Kaufman, M.D., PhD, Unit for Osteoporosis and Metabolic Bone Disease, Ghent University Hospital, Belgium. "This is the longest clinical trial of risedronate to date, ...